Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer

Affiliations

¹ University of Kentucky Markey Cancer Center, Lexington, KY, USA.
² Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15241, USA. Electronic address: brufskyam@upmc.edu.

Comment

Aju Mathew et al. Lancet Oncol. 2017 Apr.

. 2017 Apr;18(4):428-429.

doi: 10.1016/S1470-2045(17)30150-X. Epub 2017 Feb 24.

¹ University of Kentucky Markey Cancer Center, Lexington, KY, USA.
² Magee-Womens Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA 15241, USA. Electronic address: brufskyam@upmc.edu.

No abstract available

Comment on

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, Vidal M, Pernas S, López R, Muñoz M, Nuciforo P, Morales S, Oliveira M, de la Peña L, Peláez A, Prat A. Llombart-Cussac A, et al. Lancet Oncol. 2017 Apr;18(4):545-554. doi: 10.1016/S1470-2045(17)30021-9. Epub 2017 Feb 24. Lancet Oncol. 2017. PMID: 28238593 Clinical Trial.